Developing Ex Vivo Precision Gene Engineered B Cell Medicines to Create Sustainable Anti-Tumor Activity & Overcome Pharmacokinetic Shortcomings of BiTEs
Time: 2:30 pm
day: Conference Day 2
Details:
- Exploring BiTE-expressing BECMs associated with reduced tumor burden in patientderived xenograft models
- Achieving clinically meaningful serum levels of BiTE
